In a Phase 1 clinical trial, AMG133 demonstrated significant dose-dependent weight loss effects, achieving up to a 14.5% reduction in body weight compared to a 1.5% reduction for the placebo group on day 85
A patient starting at 300 pounds may see faster initial losses than someone at 200 pounds, partly because larger caloric deficits are easier to achieve at higher baseline weights
This is a common misconception
Here are the benefits of semaglutide
This means that they have not undergone review for safety, efficacy, or quality before being dispensed, and have not been demonstrated to the FDA to be safe or effective. This is transparent, honest, and something many clinics fail to disclose at all
This synergy supports consistent weight loss and helps individuals adopt healthier lifestyle habits that last